Active Biotech AB Receives Tasquinimod Milestone Payment From Ipsen for 10TASQ10 Study

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Active Biotech (NASDAQ OMX NORDIC: ACTI) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced that Active Biotech, under the terms of the co-development and commercialization agreement on the novel candidate drug tasquinimod, has received a milestone payment of 12 million euros from Ipsen.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC